Prelude Therapeutics (PRLD)
NASDAQ:PRLD
US Market

Prelude Therapeutics (PRLD) Income Statement

Compare
135 Followers

Prelude Therapeutics Income Statement

Last quarter (Q4 2024), Prelude Therapeutics's total revenue was $4.00M, an increase of 16.82% from the same quarter last year. In Q4, Prelude Therapeutics's net income was $-28.73M. See Prelude Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 7.00M$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 7.00M$ -1.17M$ -3.04M$ -2.24M$ -542.00K
Operating Expenses
$ 146.71M$ 132.28M$ 123.54M$ 113.73M$ 58.76M
Depreciation and Amortization
$ 0.00$ 1.17M$ 3.04M$ 2.24M$ 542.00K
EBITDA
$ -139.71M$ -131.11M$ -122.22M$ -112.82M$ -58.22M
Operating Income
$ -139.71M$ -132.28M$ -123.54M$ -113.73M$ -58.76M
Other Income/Expenses
$ 12.54M$ 10.45M$ 8.10M$ 2.04M$ 1.83M
Pretax Income
$ -127.17M$ -121.83M$ -115.44M$ -111.69M$ -56.93M
Net Income
$ -127.17M$ -121.83M$ -107.34M$ -110.78M$ -56.93M
Per Share Metrics
Basic EPS
$ -1.68$ -2.02$ -2.27$ -2.33$ -1.30
Diluted EPS
$ -1.68$ -2.02$ -2.27$ -2.33$ -1.30
Weighted Average Shares Outstanding
75.81M 60.36M 47.37M 47.60M 43.71M
Weighted Average Shares Outstanding (Diluted)
75.81M 60.36M 47.37M 47.60M 43.71M
Currency in USD

Prelude Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis